These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

263 related items for PubMed ID: 28559399

  • 1. Heterogeneity in Early Responses in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial).
    Dhruva SS, Huang C, Spatz ES, Coppi AC, Warner F, Li SX, Lin H, Xu X, Furberg CD, Davis BR, Pressel SL, Coifman RR, Krumholz HM.
    Hypertension; 2017 Jul; 70(1):94-102. PubMed ID: 28559399
    [Abstract] [Full Text] [Related]

  • 2. Effect of chlorthalidone, amlodipine, and lisinopril on visit-to-visit variability of blood pressure: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
    Muntner P, Levitan EB, Lynch AI, Simpson LM, Whittle J, Davis BR, Kostis JB, Whelton PK, Oparil S.
    J Clin Hypertens (Greenwich); 2014 May; 16(5):323-30. PubMed ID: 24739073
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group.
    JAMA; 2000 Apr 19; 283(15):1967-75. PubMed ID: 10789664
    [Abstract] [Full Text] [Related]

  • 6. Gene panels to help identify subgroups at high and low risk of coronary heart disease among those randomized to antihypertensive treatment: the GenHAT study.
    Lynch AI, Eckfeldt JH, Davis BR, Ford CE, Boerwinkle E, Leiendecker-Foster C, Arnett DK.
    Pharmacogenet Genomics; 2012 May 19; 22(5):355-66. PubMed ID: 22388798
    [Abstract] [Full Text] [Related]

  • 7. Characteristics and lipid distribution of a large, high-risk, hypertensive population: the lipid-lowering component of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Papademetriou V, Piller LB, Ford CE, Gordon D, Hartney TJ, Geraci TS, Reisin E, Sumner BM, Wong ND, Nwachuku C, Narayan P, Haywood J, Habib G, ALLHAT Collaborative Research Group.
    J Clin Hypertens (Greenwich); 2003 May 19; 5(6):377-84. PubMed ID: 14688492
    [Abstract] [Full Text] [Related]

  • 8. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Barzilay JI, Davis BR, Cutler JA, Pressel SL, Whelton PK, Basile J, Margolis KL, Ong ST, Sadler LS, Summerson J, ALLHAT Collaborative Research Group.
    Arch Intern Med; 2006 Nov 13; 166(20):2191-201. PubMed ID: 17101936
    [Abstract] [Full Text] [Related]

  • 9. Incidence and predictors of angioedema in elderly hypertensive patients at high risk for cardiovascular disease: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Piller LB, Ford CE, Davis BR, Nwachuku C, Black HR, Oparil S, Retta TM, Probstfield JL, ALLHAT Collaborative Research Group.
    J Clin Hypertens (Greenwich); 2006 Sep 13; 8(9):649-56; quiz 657-8. PubMed ID: 16957427
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Heart failure with preserved and reduced left ventricular ejection fraction in the antihypertensive and lipid-lowering treatment to prevent heart attack trial.
    Davis BR, Kostis JB, Simpson LM, Black HR, Cushman WC, Einhorn PT, Farber MA, Ford CE, Levy D, Massie BM, Nawaz S, ALLHAT Collaborative Research Group.
    Circulation; 2008 Nov 25; 118(22):2259-67. PubMed ID: 19001024
    [Abstract] [Full Text] [Related]

  • 12. Relationship of antihypertensive treatment regimens and change in blood pressure to risk for heart failure in hypertensive patients randomly assigned to doxazosin or chlorthalidone: further analyses from the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial.
    Davis BR, Cutler JA, Furberg CD, Wright JT, Farber MA, Felicetta JV, Stokes JD, ALLHAT Collaborative Research Group.
    Ann Intern Med; 2002 Sep 03; 137(5 Part 1):313-20. PubMed ID: 12204014
    [Abstract] [Full Text] [Related]

  • 13. The effects of antihypertensive class on gout in older adults: secondary analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
    Juraschek SP, Simpson LM, Davis BR, Shmerling RH, Beach JL, Ishak A, Mukamal KJ.
    J Hypertens; 2020 May 03; 38(5):954-960. PubMed ID: 31977576
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Rahman M, Pressel S, Davis BR, Nwachuku C, Wright JT, Whelton PK, Barzilay J, Batuman V, Eckfeldt JH, Farber M, Henriquez M, Kopyt N, Louis GT, Saklayen M, Stanford C, Walworth C, Ward H, Wiegmann T.
    Arch Intern Med; 2005 Apr 25; 165(8):936-46. PubMed ID: 15851647
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Pharmacogenetic association of the angiotensin-converting enzyme insertion/deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment: the Genetics of Hypertension-Associated Treatment (GenHAT) study.
    Arnett DK, Davis BR, Ford CE, Boerwinkle E, Leiendecker-Foster C, Miller MB, Black H, Eckfeldt JH.
    Circulation; 2005 Jun 28; 111(25):3374-83. PubMed ID: 15967849
    [Abstract] [Full Text] [Related]

  • 18. Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
    Davis BR, Piller LB, Cutler JA, Furberg C, Dunn K, Franklin S, Goff D, Leenen F, Mohiuddin S, Papademetriou V, Proschan M, Ellsworth A, Golden J, Colon P, Crow R, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group.
    Circulation; 2006 May 09; 113(18):2201-10. PubMed ID: 16651474
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Long-term renal and cardiovascular outcomes in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) participants by baseline estimated GFR.
    Rahman M, Ford CE, Cutler JA, Davis BR, Piller LB, Whelton PK, Wright JT, Barzilay JI, Brown CD, Colon PJ, Fine LJ, Grimm RH, Gupta AK, Baimbridge C, Haywood LJ, Henriquez MA, Ilamaythi E, Oparil S, Preston R, ALLHAT Collaborative Research Group.
    Clin J Am Soc Nephrol; 2012 Jun 09; 7(6):989-1002. PubMed ID: 22490878
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.